Kornimate/medical-research-clean huggingface dataset:
sintilimab (ibi308) in the neoadjuvant treatment of patients with resectable ii-iiia nsclc

Conditions: Lung Diseases; Neoplasms; Respiratory Tract Diseases; Thoracic Neoplasms; Non-small-cell Lung Cancer

Summary: the aim of this study was to investigate the safety and efficacy of sintilimab (ibi308) in patients with resectable nsclc, and to provide new treatment options for neoadjuvant therapy in patients with stage ii-iiia nsclc

sintilimab injection (ibi308) as neoadjuvant therapy in patients with resectable nsclc

Eligibility criteria:
inclusion criteria: 1. age: 18 years old to 75 years old, male or female; 2. histologically or cytologically confirmed nsclc (stage ii-iiia, american joint committee on cancer, eighth edition) that was surgically resectable; 3. being treatment-naive and the diameter of primary tumor was greater than or equal to 1 cm; 4. ecog performance status score: 0-1; 5. the function of important organs meets the following requirements (no blood components and cell growth factors are allowed for 2 weeks before the start of study): absolute neutrophil count (anc)≥1.5×10 e+9/l; platelets≥100×10e+9/l / l; hemoglobin ≥9g/dl; serum albumin(alb)≥2.8g/dl; a total bilirubin (tbil) of≤1.5 uln, alt and ast≤2.5 uln, in case of liver metastasis, alt and ast≤5 uln; creatinine clearance rate≥ 50ml/min(cockcroft-gault);thyroid function is normal. 6. estimated survival time≥3 months; 7. pd-l1 expression level ≥ 1%； 8. patients were voluntarily enrolled in the study and signed an informed consent form (icf) with good adherence and follow-up. exclusion criteria: 1. the patient has any active autoimmune disease or a history of autoimmune disease; 2. the patient is using immunosuppressive agents or systemic hormonal therapy for immunosuppression purposes (dose\>10 mg / day of prednisone or other therapeutic hormones); 3. history of interstitial lung disease; 4. severe allergic reactions to other monoclonal antibodies; 5. previous allogeneic organ transplantation or hemopoietic stem cell transplantation; 6. have clinical symptoms or disease that are not well controlled ; 7. grade iii to grade iv congestive heart failure; 8. uncontrolled hypertension; 9. artery thrombosis, embolism, or ischemia within 6 months before study treatment; 10. coagulation disorders; 11. active and uncontrolled infection; 12. the patient has previously received other pd-1 antibody therapy or other immunotherapy against pd-1/pd-l1; 13. any other known malignant tumor;

Keywords: nsclc neoadjuvant sintilimab
pet/mri artificial intelligence reconstruction algorithm air recon dl image quality evaluation and clinical study

Conditions: Parkinson&#39;s Syndrome

Summary: pet/mri artificial intelligence reconstruction algorithm air recon dl image quality evaluation and clinical study

this is a diagnostic pilot study in which 50 patients with disorders of consciousness, parkinson's syndrome and 15 prostate cancer patients were recruited to undergo pet/mri imaging to evaluate the impact of air recon dl on scanning and imaging time in different diseases and imaging sites, to determine its efficiency in clinical applications and to analyse its potential advantages in the diagnosis of specific diseases.

Eligibility criteria:
inclusion criteria: * 1. adults between the ages of 18 and 75 who are autonomous; 2. persons with good compliance; 3. those who are mentally alert and able to move around on their own; 4. those who agree to participate in this clinical trial and sign the informed consent form. exclusion criteria: * 1. persons who do not have full capacity for civil behaviour; 2. women during pregnancy and breastfeeding; 3. other implants, prostheses, foreign bodies and patches with electronic implants such as pacemakers, insulin pumps and cochlear implants that are not suitable for mri; 4. patients with claustrophobia; 5. those who, in the opinion of the investigator, are not suitable for participation in this clinical trial.

Keywords: artificial intelligence reconstruction algorithms air recon dl pet/mri
assessment of the efficacy of injectable hyaluronic acid for genitourinary syndrome of menopause

Conditions: Genitourinary Syndrome of Menopause

Summary: the vaginal wall consists of epithelium, lamina propria, muscularis and adventitia (1). the decrease in postmenopausal estrogen levels causes thinning of the vaginal wall thickness and the development of genitourinary menopause syndrome (gsm), which is characterized by vaginal dryness, burning, pruritus, urinary complaints and sexual discomfort (2). in the treatment of gsm symptomatology, there are many different non-hormonal treatment options such as vaginal topical agents and energy-based devices, as well as estrogen-based hormonal therapies (3). the main problem with non-hormonal treatments is the short-term resolution of vaginal atrophy and the lack of long-term results, while contraindications such as breast cancer history and unwillingness of the women to use hormones are problematic for estrogen-based treatments. considering all these issues, there is a search for new therapeutic agents with long and high efficiency and safety profile in the treatment of gsm. hyaluronic acid (ha) which is one of the main components of the extracellular matrix and has water-binding property that provides moisturizing and lubricating effect (4). besides, it is also reported as the key to the process of tissue regeneration through inflammation, cellular migration and angiogenesis (5). for these reasons, it seems to be a promising treatment of gsm symptomatology. ha has many routes of administration, such as vaginal gels, ovules, and suppositories, and studies have shown that locally applied ha preparations have a short-term therapeutic effect on gsm symptoms (6). however, there is no consensus regarding ha efficacy due to heterogeneity of studies. since it is an endogenous molecule, it can be thought that it will be more effective if it is injected directly into the epithelium rather than locally applied. the injectable form of multifractional intercalated cross-linked ha (mic-ha) (armonia®, regenyal, italy) is designed for the reinforcement of the extracellular matrix in the female genital area. we intend to investigate and objectively evaluate the efficacy of mic-ha injection on gsm symptoms and sexual functions in postmenopausal women.


Eligibility criteria:
inclusion criteria: vaginal dryness burning itching dyspareunia genital discomfort - exclusion criteria: presence of pelvic organ prolapse vaginal infections history of genital carcinoma vulvovaginal dystrophic diseases previous vaginal surgery current use of vaginal moisturizer or lubricant, and use of estrogen history of allergies to hyaluronic acid, betadine or lidocaine

Keywords: vulvovaginal atrophy hyaluronic acid menopause sexual dysfunction
clinical correlation evaluation of the liverfast test for diagnosing important liver lesions of fibrosis and steatosis against magnetic resonance elastography (mre) for liver fibrosis and mr-based assessment of steatosis, in adult us population.

Conditions: Liver Fibrosis Due to NASH; MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Alcohol Liver Disease

Summary: this is a retrospective cross-sectional research intended to explore the utility of liverfast in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the magnetic resonance elastography (mre) and mrct1 fibrosis classification (historical records) and to assess liverfast performance for mr steatosis assessment in an united states adult miscellaneous population with available (historical) mr intracellular fat fraction assessment (icff) from a single tertiary us clinic.

1. to assess the correlation and the strength of concordance of liverfast for staging important liver lesions of fibrosis and steatosis against mr liver assessment of clinically significant (≥f2 stage), advanced fibrosis (≥f3 stage) and cirrhosis (f4 stage) (mre, ct1) and steatosis (mr) in a sld (masld, metald) adult us population. 2. to assess the diagnostic performance \[auroc (95%ci)\] of liverfast for diagnosing important liver lesions of fibrosis, steatosis taking mr-based methods as surrogate gold-standard (mre for fibrosis assessment and mr for steatosis quantification).

Eligibility criteria:
inclusion criteria: * sld with masld or metald adult patients with: * available historical report of mre and liverfast test * at least fibrosis scoring available (steatosis and necro-inflammation imaging reports are requested equally when available). * other imaging modality reports ie. mri, arfi, ct1, swe and fibroscan can be included when available exclusion criteria: * participants identified as having risk factors for false positive/negative results for liverfast (severe intravascular hemolysis-if condition is known-, acute hepatitis or severe cytolysis with ≥ 600 alt values) * other comorbidities not compatible with the diagnosis of masld or metald

Keywords: liverfast liverfast test noninvasive test for the liver liverfast for masld liverfast for mash fibronostics liverfast fibrosis test liverfast steatosis test liverfast for masld and mash liverfast for liver fibrosis liverfast plus mre liverfast and mre liverfast and other imaging tools
integrated treatment and prevention for people who inject drugs

Conditions: HIV Positive

Summary: the purpose of this study is to determine the feasibility of a future trial that will assess whether an integrated intervention combining psychosocial counseling and supported referrals for antiretroviral therapy (art) at any cd4 cell count and substance use treatment for hiv-infected people who inject drugs (pwid) will reduce hiv transmission to hiv-uninfected injection partners, as compared to routine care dictated by national guidelines for hiv-infected pwid.

this is a multi-site, two-arm, randomized, vanguard study. network units will consist of an hiv-infected index participant and his/her hiv-uninfected network injection partner(s). network units will be randomized to the intervention or standard of care arms in a 1:3 ratio, stratified by site. to assess feasibility of the intervention, additional interviews will be conducted with study staff (systems navigators and counselors) and clinic-based stakeholders at each study site. approximately 500 index participants and their partners will be enrolled.

Eligibility criteria:
inclusion criteria: index participants: * age 18-45 years at the screening visit (age verification procedures will be defined in the study specific procedures \[ssp\] manual) * able to provide informed consent * active injection drug user, defined as self-report of: a) injecting drugs approximately two or more times per week for the past three months, and b) ability to identify the anatomical location of the most recent injection site, as determined by study staff * reports sharing needles/syringes or drug solutions at least once in the last month * hiv-infected based on a study-defined testing algorithm (defined in the ssp manual) * viral load ≥1,000 copies/ml at screening * willing and able to identify, recruit, and have enrolled at least one hiv-uninfected network injection partner who is eligible for study participation according to the criteria below * have no plans to move outside the study area for at least one year after study enrollment * willing to participate in intervention activities, including regular phone contact hiv uninfected injection partners: * age 18-45 years at the screening visit (age verification procedures will be defined in the ssp manual) * able to provide informed consent * active injection drug user, defined as: a) self-report of injecting drugs approximately two times per week for the past three months, and b) ability to identify the anatomical location of the most recent injection site, as determined by study staff * confirmed injection partner, using referral identification cards, of index participant within the past 1 month * hiv-uninfected based on the study-defined testing algorithm\* (defined in the study ssp manual) * have no plans to move outside the study area for at least one year after study enrollment exclusion criteria: -
achilles tendon and balance in prediabetes

Conditions: PreDiabetes

Summary: the aim was to evaluate the achilles tendon size and static and dynamic balance, as well as the role of achilles tendon on balance in prediabetes. a total of 96 patients were divided into three groups: 1)the control group, consisting of patients without diabetes; 2)the prediabetes group; 3)the diabetes mellitus group. ultrasonographic measurements of achilles tendon sizes were performed. dynamic balance was assessed using the berg balance scale, static balance was assessed.the self-leeds assessment of neuropathic symptoms and signs was utilized to identify neuropathic pain.

background/aims: there is a lack of studies that examine balance problems and achilles tendon thickness in prediabetes, despite their common occurrence in diabetes. the aim was to evaluate the achilles tendon size and static and dynamic balance, as well as the role of achilles tendon on balance in prediabetic patients. methods: a total of 96 patients were divided into three groups: 1)the control group, consisting of patients without diabetes; 2)the prediabetes group; 3)the diabetes mellitus group. ultrasonographic measurements of achilles tendon sizes (thickness, width and area) were performed. dynamic balance was assessed using the berg balance scale, static balance (the fall index, stability indexes) was assessed using a tetrax device. the self-leeds assessment of neuropathic symptoms and signs was utilized to identify neuropathic pain.

Eligibility criteria:
inclusion criteria: * being between 40 and 65 years old exclusion criteria: * extremity amputation * vitamin b12 deficiency * type 1 diabetes mellitus * prior exposure to neurotoxic agents * peripheral neuropathy for reasons such as chronic kidney failure, liver failure, - hypothyroidism, hereditary and inflammatory peripheral neuropathies, neuromuscular diseases, malignancies * anti-neuropathic drug usage * radiculopathy * nerve trauma or surgery * vasculitis and autoimmune disorders * peripheral vascular disease * pregnancy * vestibular and cerebellar problems * history of lower extremity surgery * presence of medication affecting balance * history of alcoholism * presence of visual impairment.

Keywords: achilles tendon balance prediabetes
exercise and manual therapy for shoulder subacromial impingement syndrome

Conditions: Shoulder Impingement Syndrome

Summary: the purposes of this study are to: 1. determine if a rehabilitation program that consists of exercise and manual therapy reduces pain and improves quality of life in patients with shoulder subacromial impingement syndrome; 2. determine which patients are likely to respond to this rehabilitation program and which patients are not likely to respond to this rehabilitation program the hypotheses are: 1. the rehabilitation treatment program will result in significant changes in pain and quality of life 2. there will be items from the history and examination that will identify those patients who respond favorably and those who do not respond favorably to rehabilitation at 6 weeks, 3, 6 and 12 months.

subacromial impingement syndrome (sais) is the most frequent cause of shoulder pain. a variety of non-surgical treatments have been advocated to correct the impairments associated with sais. clinical trials support the use of therapeutic exercise and joint mobilizations to improve pain and functional disability associated with sais. however, not all patients in these trials had a favorable outcome. moreover, the effect sizes in these trials were small to moderate. thus the purposes of this study are to 1. determine the effect of a multi-modal rehabilitation program consisting of strengthening, stretching, manual therapy to the shoulder and spine, patient education, posture, and functional re-training; and 2. identify those patients who are and who are not likely to respond to rehabilitation at the start of care.

Eligibility criteria:
inclusion criteria: * diagnosis of shoulder impingement syndrome as evidence by all 5 criteria: 1. reproduction of symptoms with impingement test: either hawkins-kennedy or neer test 2. pain during active shoulder elevation at or above 60 degrees 3. weakness of rotator cuff or pain during the empty can test or during resisted shoulder external rotation 4. shoulder disability: greater than or equal to 20/100 (0 = no disability) 5. able to understand written and spoken english exclusion criteria: * severe pain; pain is \> or equal to 7/10 on nprs (0 = no pain) * shoulder surgery on affected shoulder * traumatic shoulder dislocation within the past 3 months * previous rehabilitation for this episode of shoulder pain * reproduction of shoulder pain with active or passive cervical motion * systemic inflammatory joint disease * global loss of passive shoulder rom, indicative of adhesive capsulitis

Keywords: shoulder pain shoulder impingement syndrome manual therapy rehabilitation
nudging for vaccination : efficacity and acceptability among medical students

Conditions: Influenza, Human; Vaccination; Sepsis

Summary: nudge is a set of methods aimed at helping people adopt a behavior by a gentle prompt, conscious or not. classically, nudges rely on heuristics and cognitive biases. these methods have been studied for years in social psychology and are receiving renewed attention since the awarding of the nobel prize in economics to richard thaler for his work on the application of nudge to the economy. health professionals are very inadequately vaccinated (25 to 45% of the population). some studies have shown that a nudge based on intent implementation can significantly increase vaccination coverage. however, few studies evaluate the acceptability of nudge or its application to health professionals. the investigators sought to apply a nudge based on availability heuristics to health professionals, in order to evaluate its effectiveness and terms of behavior adoption (influenza vaccination) and its acceptability. the investigator's hypothesis is that nudging is both effective and acceptable and that people found nudging more acceptable if they have been exposed to a nudge.

the investigators asked residents in general medicine to pass a questionnaire including a nudge. this nudge was the influenza vaccine prescription form accompanied on the back of the telephone numbers of the occupational health centers of the hospitals where residents were on probation. the interns of the group "nudge" saw at the end of their questionnaire the following statement: "if you are not vaccinated against the flu so far, you can get the form stapled to this questionnaire, it will allow you to get the vaccine in pharmacy. on the back you will also find practical information about immunization services at your place of training. " a group will receive an implemented nudge questionnaire, a group will receive a questionnaire without nudge and a control group will not be asked. (phase 1) the 3 groups will receive a month later a questionnaire evaluating the effectiveness in terms of immunization coverage, and the acceptability of the nudge, for oneself and for others. (phase 2) the control group will only receive the phase 2 questionnaire to control the hawthorne effect. the difference between the 3 groups will consist exclusively in the exposure of the participants to: * a questionnaire on their attitude (opinion) towards vaccination; * the numbers of the occupational health vaccination centers of their places of training; * the flu vaccine prescription form, to be signed and stamped by a doctor (also already freely available on the internet)

Eligibility criteria:
inclusion criteria: * medical students exclusion criteria: * none

Keywords: nudge acceptability
analgesic and appetite-stimulating effects of cannabigerol and thc (ascent)

Conditions: Pain; Appetite Loss; Abuse, Drug

Summary: this study will assess the analgesic, appetite-stimulating, and subjective effects of cannabigerol (cbg) alone and in combination with thc.

the overall aim of this double-blind, placebo-controlled, within-subject study in healthy, occasional cannabis smokers is to ascertain the dose-dependent analgesic and appetite-stimulating effects of ecologically relevant doses of cannabigerol (cbg) alone and in combination with a sub-analgesic / sub-appetite stimulating, minimally psychoactive dose of thc and an analgesic, appetite-stimulating, but intoxicating dose of thc.

Eligibility criteria:
inclusion criteria: * male or non-pregnant and non-lactating females aged 21-55 years * • report occasional use of cannabis (cannabis use between ≥ biweekly and ≤ 3 days per week) over the month prior to screening * not currently seeking treatment for their cannabis use * have a body mass index from 18.5 - 34kg/m2. * able to perform all study procedures * must be using a contraceptive (hormonal or barrier methods) * females must not be lactating exclusion criteria: * meeting dsm-v criteria for moderate-severe cannabis use disorder (cud) or any substance use disorder other than nicotine, caffeine, or mild cud * any other axis i disorder * • current use of any medications within 14 days or 5 half-lives of administration (whichever is longer) except for hormonal contraceptives in females. if a medication is taken once a participant is enrolled, sessions will be suspended for 14 days or 5 half-lives after administration (whichever is longer) * if medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures. * current pain * pregnancy is exclusionary due to the possible effects of the study medication on fetal development. * history of an allergic reaction or adverse reaction to cannabis is exclusionary. * history of respiratory illness or current respiratory illness * currently enrolled in another research protocol * not using a contraceptive method (hormonal or barrier methods) * insensitivity to the cold water stimulus of the cold pressor test * any disorders that might make cannabis administration hazardous are exclusionary, as determined by the evaluating physician

Keywords: analgesia pain appetite thc cannabigerol cbg
a 1-year study on the effects of cp-945,598 for the treatment of obesity in overweight type 2 diabetic patients

Conditions: Obesity

Summary: the purpose of this study is to determine if cp-945,598 is effective in the treatment of obesity in type 2 diabetic patients.

the cp-945,598 program was terminated on november 3, 2008 due to changing regulatory perspectives on the risk/benefit profile of the cb1 class and likely new regulatory requirements for approval. no safety issues were involved in the termination decision.

Eligibility criteria:
inclusion criteria: * subjects must be overweight (bmi 27- 50 kg/m2) * subjects must have type 2 diabetes mellitus exclusion criteria: * pregnancy * serious or unstable current or past medical conditions
computerized cognitive bias intervention for intolerance of uncertainty

Conditions: Intolerance of Uncertainty; Anxiety

Summary: this investigation examines the efficacy of a brief, one-session computerized interpretation bias modification paradigm (cbm-i) in the reduction of intolerance of uncertainty. intolerance of uncertainty is a risk factor for the development and maintenance of various forms of psychopathology.


Eligibility criteria:
inclusion criteria: * elevated iu interpretation bias at pre-intervention. exclusion criteria: * none.

Keywords: intolerance of uncertainty anxiety